ESR1 and breast carcinoma: Patients diagnosed with ERα(−) breast cancer normally have lower survival but higher recurring rates than ERα(+) breast cancer patients due in part to a loss of target therapy such as tamoxifen, which is designed to interrupt the function of ERα.